ArticleAntibiotics (Basel, Switzerland)2021
The Treatment of Peri-Implant Diseases: A New Approach Using HYBENX
Article in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- The Use of Molecular Biology Methods to Evaluate the Activity of Different Topical Treatments Against Periodontal Pathogen Bacteria.Pathogens (Basel, Switzerland) · 2026Article
- An in vitro study exploring a new method for managing peri-implant disease using the ten second technique.Scientific reports · 2025Article
- Exploring the Potential of Micro-Immunotherapy in the Treatment of Periodontitis.Life (Basel, Switzerland) · 2024Review
- A Local Desiccant Antimicrobial Agent as an Alternative to Adjunctive Antibiotics in the Treatment of Periodontitis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Assessment of Dentinal Tubules Penetration by Hyben X Delivered into the Root Canal System as an Irrigant; AnIranian endodontic journal · 2023Article
- The Effectiveness of a Bioactive Healing Abutment as a Local Drug Delivery System to Impact Peri-Implant Mucositis: A Prospective Case Series Study.Pharmaceutics · 2022Article
- Cytotoxic Effects on Gingival Mesenchymal Stromal Cells and Root Surface Modifications Induced by Some Local Antimicrobial Products Used in Periodontitis Treatment.Materials (Basel, Switzerland) · 2021Article
- Methods of Topical Administration of Drugs and Biological Active Substances for Dental Implants-A Narrative Review.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeri-implantitis is a pathological condition characterized by an inflammatory process involving soft and hard tissues surrounding dental implants. The management of peri-implant disease has several protocols, among which is the chemical method HYBENX
methodsThe present study included a population of ten subjects with severe peri-implantitis. The procedure used in the study involves the application of HYBENX
resultsAt baseline, a mean pocket probing depth (PPD) of 7.3 ± 0.5 mm and a mean clinical attachment level (CAL) of 8.8 ± 0.8 mm was recorded. An average residual PPD of 4.2 ± 0.5 mm and a mean CAL of 5.2 ± 0.8 mm were observed after 1 year. Additionally, the average of bone gain was about 3.4 mm, with a mean marginal bone level (MBL) change from 5.8 mm (baseline) to 2.4 mm (12 months). In total, 90% of the treated implants reached the success rate after the 1-year follow-up. Only in one case out of ten treated implants was resolution of the disease not achieved.
conclusionClinical improvements highlight that the procedure of open-flap debridement (OFD) + HYBENX
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.